Short answer
CG Oncology, Inc. (CGON) filed an 8-K current report with the SEC on May 26, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). President & COO Ambaw Bellete departing effective June 30, 2026 under planned separation agreement.
CG Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- President & COO Ambaw Bellete departing effective June 30, 2026 under planned separation agreement
- Severance governed by Section 4(b) of Bellete’s January 9, 2025 employment agreement
- Arthur Kuan appointed President while retaining his existing positions
- Chief Commercial Officer search initiated, creating near-term commercial leadership transition risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CG Oncology, Inc. 8-K filings
Get the next CGON 8-K as it lands
Follow CGON for push alerts, or ask the research agent what this filing means.